Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
Trailing Twelve Months EPS: ($0.93)
2025 EPS Estimate: ($0.97)
2026 EPS Estimate: ($1.41)
- Current Stock Price
- $34.05
- Consensus Rating
- Buy
- Ratings Breakdown
- 13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $106.75 (213.5% Upside)
